Viewing Study NCT04837651


Ignite Creation Date: 2025-12-24 @ 11:47 PM
Ignite Modification Date: 2025-12-31 @ 4:36 PM
Study NCT ID: NCT04837651
Status: COMPLETED
Last Update Posted: 2021-08-02
First Post: 2021-03-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
Sponsor: Dragonfly Research, LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module